Report Viewer

NINDS CDE Notice of Copyright
Motor Function Measure (MFM)
Availability
Contact : Dr. Carole BÉrard
Phone:33 (0)4 72 12 95 04
 
or
 
For further information, consult the website: Motor Function Measure Website
 
The 2nd edition English translation was revised and corrected in December 2009 (validated by the steering committee). User Manual or the Score Sheet
Classification
Supplemental: Congenital Muscular Dystrophy (CMD)
 
Exploratory: Mitochondrial Disease (Mito)
Short Description of Instrument
The Motor Function Measure (MFM) is a generic scale which provides a measurement of the effects of muscle weakness in neuromuscular diseases (NMD). Assessments are based on posture and movements of the whole body.
This tool makes it possible to follow the evolution of the patients, and to anticipate certain events such as the loss of ability to walk. The MFM can be used to evaluate the effectiveness of therapeutic measures.
Rationale/Justification
Strengths/Weaknesses: Measures patient important functions, excellent reliability and validity, sensitive to change, large age range, possible in ambulatory and non-ambulatory children, measures arm/leg and gross/fine motor function.
Time consuming, ceiling effect in more able patients, not determined whether it measures the acitivites in daily life patients with mitochondrial disease are most limited in (items were included based on experience in patients with neuromuscular disease), dependent on cooperation of the patient
 
Psychometric Properties: Internal consistency 0.99. Inter- and intrarater reliability 0.96-0.99 in neuromuscular disorders. Correlation with physicians and physiotherapists' severity score 0.88 and 0.91. High correlation between MFM and Brooke, Vignos, WeeFIM in neuromuscular disorders. Predictive for loss of ambulation in patients with DMD.
This instrument has been specifically applied in Duchenne muscular dystrophy, Spinal muscular atrophy, and congential myopathy.
 
Validated in populations:
• Duchenne muscular dystrophy,
• Becker's muscular dystrophy (BMD),
• Facio-scapulo-humeral dystrophy (FSHD)
• Limb girdle muscular dystrophy (LGMD)
• Myotonic dystrophy (DM)
• Spinal muscular atrophy (SMA)
• Congenital myopathy (CM) and congenital muscular dystrophy (CMD)
• Hereditary neuropathy (HN)
References
Vuillerot C, Meilleur KG, Jain M, Waite M, Wu T, Linton M, Datsgir J, Donkervoort S, Leach ME, Rutkowski A, Rippert P, Payan C, Iwaz J, Hamroun D, BÉrard C, Poirot I, BÖnnemann CG. English cross-cultural translation and validation of the neuromuscular score: a system for motor function classification in patients with neuromuscular diseases. Arch Phys Med Rehabil. 2014;95(11):2064-2070.
 
Vuillerot C, Rippert P, Kinet V, Renders A, Jain M, Waite M, Glanzman AM, Girardot F, Hamroun D, Iwaz J, Ecochard R, Quijano-Roy S, BÉrard C, Poirot I, BÖnnemann CG; CDM MFM study group. Rasch Analysis of the Motor Function Measure in Patients with Congenital Muscle Dystrophy and Congenital Myopathy. Arch Phys Med Rehabil. 2014.
 
Capucine de Lattre, Christine Payan, Carole Vuillerot, Pascal Rippert, Denis de Castro, Carole BÉrard, Isabelle Poirot and the MFM-20 Study Group. Motor Function Measure: validation of a short form (MFM-20) for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013. 94 : 2218-26.
 
Carole Vuillerot, MD, PhD, Christine Payan, MD, Françoise Girardot, SRP, Jacques Fermanian, MD, PhD, Jean Iwaz, PhD, Carole BÉrard, MD, RenÉ Ecochard, MD, PhD, the MFM Study Group. Responsiveness of the Motor Function Measure in Neuromuscular Diseases. Arch Phys Med Rehabil Dec 2012; 93(12):2551-2556.
 
Vuillerot C, Girardot F, Payan C, Fermanian J, Iwaz J, De Lattre C, Berard C. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Dev Med Child Neurol. 2010;52(1):60-5.
 
C. Benaïm, S. Sacconi, M. Fournier-Mehouas, V. Tanant, C. Desnuelle. Validity of the motor function measurement scale when routinely used in the follow-up of adult outpatients in a neuromuscular center. Revue Neurologie 2010. 166: 49-53.
 
BÉrard C, Payan C, Fermanian J, Girardot F; Groupe d'Etude MFM. [A motor function measurement scale for neuromuscular diseases - description and validation study]. Rev Neurol (Paris). 2006;162(4):485-93. French.
 
BÉrard C, Payan C, Hodgkinson I, Fermanian J and the MFM collaborative study group. A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscular Disorders. 2005. 15: 463-470.

 

Document last updated June 2019